$84.810
0.000 (0.00%)收盤時
WGS 資訊
WGS 事件
GeneDx Launches New Online Exome Testing Service
GeneDx announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay, GDD, intellectual disability, ID, or epilepsy. "For too many families, the path to answers is defined by delays, barriers, and a system that isn't built for the realities they face," said Katherine Stueland, CEO of GeneDx. "By making exome testing simpler and easier to access, we can reach more children who need answers and move closer to a healthcare system that delivers on the promise of precision medicine."
Sees Q3 Exome and Genome Volume at 33,200 Tests
Sees Q3 exome and genome volume 33,200 tests; exome and genome revenue $110M-$112M; adjusted gross margin approximately 70%
Sees FY26 Exome and Genome Volume Growth of at Least 30%
Sees FY26 exome and genome volume at least 30% growth; exome and genome revenue at least 20% growth; adjusted gross margin approximately 70%
GeneDx Q2 Revenue of $114.4M Beats Expectations
Reports Q2 revenue $114.4M, consensus $111.01M. "Our team's unwavering focus and agility drove a strong second quarter. By delivering healthy revenue, volume, and gross margin growth, we successfully navigated our return to profitability," said Katherine Stueland, CEO of GeneDx. "We are managing the transition to genome testing, making progress on each of our key imperatives - optimizing unit economics, growing utilization, and delivering the best products at unmatched scale - while continuing to extend our industry-leading position in both exome and genome testing to reach as many patients and families as soon as possible."
GeneDx Appoints Mark Gardner as President
GeneDx announced the appointment of Mark Gardner as President, effective June 15, 2026. Reporting to Katherine Stueland, Chief Executive Officer, Gardner will lead GeneDx's commercial and operations teams
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。